Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Argent Biopharma ( (AU:RGT) ) has shared an update.
Argent BioPharma Ltd. has announced a refinancing agreement with Mercer Street Global Opportunity Fund, LLC, which involves amending the minimum conversion price of 250,000 convertible notes from A$10.00 to A$0.11. This adjustment is part of a broader strategy to amend terms of existing convertible note facilities, potentially impacting the company’s financial flexibility and market positioning.
More about Argent Biopharma
Argent BioPharma Limited (ASX: RGT) is a clinical-stage biopharmaceutical company specializing in neuroimmunology and advanced nanomedicine. The company focuses on developing cannabinoid-based therapeutics and neuroimmune modulation, with a pipeline that includes products like CannEpil®, CogniCann®, and CimetrA® targeting CNS disorders and immune-related conditions.
YTD Price Performance: -20.83%
Average Trading Volume: 554
Technical Sentiment Signal: Buy
Current Market Cap: $6.65M
For a thorough assessment of RGT stock, go to TipRanks’ Stock Analysis page.